Granulocyte-macrophage colony stimulating factor biosimilar - North China Pharmaceutical Corporation

Drug Profile

Granulocyte-macrophage colony stimulating factor biosimilar - North China Pharmaceutical Corporation

Alternative Names: HUABEI JIMUXIN; Jimuxin; rhGM-CSF - North China Pharmaceutical Corporation

Latest Information Update: 30 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator North China Pharmaceutical Corporation
  • Developer North China Pharmaceutical Corporation; Peking Union Medical College Hospital
  • Class Adjuvants; Glycoproteins; Granulocyte-macrophage colony-stimulating factors
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Leucopenia
  • Phase II Pulmonary alveolar proteinosis

Most Recent Events

  • 30 Dec 2016 Granulocyte-macrophage colony stimulating factor biosimilar is still in phase II trials for Pulmonary alveolar proteinosis in China (Inhalation)
  • 26 Sep 2014 Launched prior to this date for Leucopenia (Chemotherapy-induced) in China (SC)
  • 26 Sep 2014 Launched prior to this date for Leucopenia (Radiotherapy-induced) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top